Takeda holder plans sale of 54,210 ADSs
A holder of Takeda Pharmaceutical Company Limited American Depositary Shares plans to sell up to 54,210 ADSs on the NYSE, through Interactive Brokers LLC, with an indicated aggregate market value of $908,019.02 as of 07/13/2026.
Rhea-AI Filing Summary
A holder of Takeda Pharmaceutical Company Limited American Depositary Shares plans to sell up to 54,210 ADSs on the NYSE, through Interactive Brokers LLC, with an indicated aggregate market value of $908,019.02 as of 07/13/2026.
The securities relate to Restricted Stock Unit awards that vested on 07/01/2026, when 114,144 ADSs were acquired as compensation.
Positive
- None.
Negative
- None.
Filing Explained
The filing reports a proposed 114,144-ADS disposition from vested compensation, without establishing completion or new dilution for existing holders.
The July 13 Form 144 lists 114,144 ADSs under securities to be sold, but the filing does not establish that the ADSs were sold.
The ADSs are identified as acquired through vested restricted stock unit awards and classified as compensation. This is a disposition by the filer, not a Takeda issuance, so the filing discloses no new ADS issuance or dilution for existing common holders.
The provided filing contains no trading-plan disclosure, sale price, or remaining-holdings information, so the size of any change in the filer's ownership cannot be assessed.
Key Figures
Key Terms
Restricted Stock Unit Awards financial
compensation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What amount of Takeda (TAK) ADSs is planned for sale under this notice?
What is the aggregate market value of the Takeda (TAK) ADSs covered by this sale?
When were the Takeda (TAK) ADSs underlying this Form 144 acquired?
How many Takeda (TAK) ADSs were received from vested RSU awards?
On which exchange will the Takeda (TAK) ADSs be sold?
AI-generated analysis. How Rhea-AI works. Not financial advice.